FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:877-887 February 28, 2008 Number 9 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Editorial by Parrillo, J. E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Vasopressin is commonly used as an adjunct to catecholamines to support blood pressure in refractory septic shock, but its effect on mortality is unknown. We hypothesized that low-dose vasopressin as compared with norepinephrine would decrease mortality among patients with septic shock who were being treated with conventional (catecholamine) vasopressors.

Methods In this multicenter, randomized, double-blind trial, we assigned patients who had septic shock and were receiving a minimum of 5 µg of norepinephrine per minute to receive either low-dose vasopressin (0.01 to 0.03 U per minute) or norepinephrine (5 to 15 µg per minute) in addition to open-label vasopressors. All vasopressor infusions were titrated and tapered according to protocols to maintain a target blood pressure. The primary end point was the mortality rate 28 days after the start of infusions.

Results A total of 778 patients underwent randomization, were infused with the study drug (396 patients received vasopressin, and 382 norepinephrine), and were included in the analysis. There was no significant difference between the vasopressin and norepinephrine groups in the 28-day mortality rate (35.4% and 39.3%, respectively; P=0.26) or in 90-day mortality (43.9% and 49.6%, respectively; P=0.11). There were no significant differences in the overall rates of serious adverse events (10.3% and 10.5%, respectively; P=1.00). In the prospectively defined stratum of less severe septic shock, the mortality rate was lower in the vasopressin group than in the norepinephrine group at 28 days (26.5% vs. 35.7%, P=0.05); in the stratum of more severe septic shock, there was no significant difference in 28-day mortality (44.0% and 42.5%, respectively; P=0.76). A test for heterogeneity between these two study strata was not significant (P=0.10).

Conclusions Low-dose vasopressin did not reduce mortality rates as compared with norepinephrine among patients with septic shock who were treated with catecholamine vasopressors. (Current Controlled Trials number, ISRCTN94845869 [controlled-trials.com] .)

Source Information

From the iCAPTURE Centre, Vancouver, BC (J.A.R., K.R.W., A.C.G., M.M.S.); St. Paul's Hospital, Vancouver, BC (J.A.R., K.R.W., J.S., A.C.G., M.M.S., D.A.); Ottawa Hospital, University of Ottawa, Ottawa (P.C.H.); Kelowna General Hospital, Kelowna, BC, and University of British Columbia, Vancouver (C.L.H.); Mount Sinai Hospital, Toronto (S.M.); Toronto General Hospital, Toronto Western Hospital, and University of Toronto, Toronto (J.T.G.); and St. Joseph's Hospital and McMaster University, Hamilton, ON (D.J. Cook) — all in Canada; and Alfred Hospital and Monash University, Melbourne (D.J. Cooper); and Royal Melbourne Hospital and University of Melbourne (J.J.P.) — all in Melbourne, Australia.

Address reprint requests to Dr. Russell at Critical Care Medicine, St. Paul's Hospital, 1081 Burrard St., Vancouver, BC V6Z 1Y6, Canada, or at jrussell{at}mrl.ubc.ca.

Full Text of this Article

Related Letters:

Vasopressin in Septic Shock
Boyle W. A., Leone M., Dünser M. W., Hasibeder W. R., Wenzel V., Landry D. W., Oliver J. A., Mogyorosi A., Russell J. A., Walley K. R.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:2736-2738, Jun 19, 2008. Correspondence

This article has been cited by other articles:

• The COIITSS Study Investigators, (2010). Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults: A Randomized Controlled Trial. JAMA 303: 341-348 [Abstract] [Full Text]  
• Nakada, T.-a., Russell, J. A., Boyd, J. H., Aguirre-Hernandez, R., Thain, K. R., Thair, S. A., Nakada, E., McConechy, M., Walley, K. R. (2010). {beta}2-Adrenergic Receptor Gene Polymorphism Is Associated with Mortality in Septic Shock. Am. J. Respir. Crit. Care Med. 181: 143-149 [Abstract] [Full Text]  
• Maier, S., Hasibeder, W., Pajk, W., Hengl, C., Ulmer, H., Hausdorfer, H., Wurzinger, B., Knotzer, H. (2009). Arginine-vasopressin attenuates beneficial norepinephrine effect on jejunal mucosal tissue oxygenation during endotoxinaemia. Br J Anaesth 103: 691-700 [Abstract] [Full Text]  
• Choong, K., Bohn, D., Fraser, D. D., Gaboury, I., Hutchison, J. S., Joffe, A. R., Litalien, C., Menon, K., McNamara, P., Ward, R. E., on behalf of the Canadian Critical Care Trials Gro, (2009). Vasopressin in Pediatric Vasodilatory Shock: A Multicenter Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. 180: 632-639 [Abstract] [Full Text]  
• Ware, L. B., Eisner, M. D., Flaherty, K. R. (2009). Clinical Year in Review II: Sepsis, Mechanical Ventilation, Occupational and Environmental Lung Disease, and Sleep. Proc Am Thorac Soc 6: 494-499 [Full Text]  
• Joseph, J., Sinha, A., Paech, M., Walters, B. N J (2009). Sepsis in pregnancy and early goal-directed therapy. Obstet Med 2: 93-99 [Abstract] [Full Text]  
• Dunser, M. W., Hasibeder, W. R. (2009). Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress. J Intensive Care Med 24: 293-316 [Abstract]  
• Mongardon, N., Dyson, A., Singer, M. (2009). Pharmacological optimization of tissue perfusion. Br J Anaesth 103: 82-88 [Abstract] [Full Text]  
• Cao, Z., Gao, Y., Tao, G. (2009). Vasoplegic Syndrome During Liver Transplantation. Anesth. Analg. 108: 1941-1943 [Abstract] [Full Text]  
• Fowler, R. A., Adhikari, N. K. J., Scales, D. C., Lee, W. L., Rubenfeld, G. D. (2009). Update in Critical Care 2008. Am. J. Respir. Crit. Care Med. 179: 743-758 [Full Text]  
• Lameire, N., van Biesen, W., Hoste, E., Vanholder, R. (2009). The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury. NDT Plus 2: 1-10 [Abstract] [Full Text]  
• Zimmerman, J. L. (2009). Hemodynamic Monitoring and Shock. ACCP Pulmonary Med Brd Rev 25: 345-358 [Full Text]  
• Cathie, K, Levin, M, Faust, S N (2008). Drug use in acute meningococcal disease. EDUCATION AND PRACTICE 93: 151-158 [Full Text]  
• Liu, K. D., Levitt, J., Zhuo, H., Kallet, R. H., Brady, S., Steingrub, J., Tidswell, M., Siegel, M. D., Soto, G., Peterson, M. W., Chesnutt, M. S., Phillips, C., Weinacker, A., Thompson, B. T., Eisner, M. D., Matthay, M. A. (2008). Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. Am. J. Respir. Crit. Care Med. 178: 618-623 [Abstract] [Full Text]  
• Sharman, A., Low, J. (2008). Vasopressin and its role in critical care. Contin Educ Anaesth Crit Care Pain 8: 134-137 [Full Text]  
• Boyle, W. A., Leone, M., Dunser, M. W., Hasibeder, W. R., Wenzel, V., Landry, D. W., Oliver, J. A., Mogyorosi, A., Russell, J. A., Walley, K. R. (2008). Vasopressin in Septic Shock. NEJM 358: 2736-2738 [Full Text]  
• Daley, M. R., Seam, N., Luboshitzky, R., Qupti, G., Bollaert, P.-E., Marik, P. E., Pastores, S. M., Kavanagh, B. P., Manoach, S., Sprung, C. L., Singer, M., Annane, D., the CORTICUS Study Group, (2008). Corticosteroids for Septic Shock. NEJM 358: 2068-2071 [Full Text]  
• (2008). Vasopressin in Septic Shock. JWatch Emergency Med. 2008: 3-3 [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 336: 530-531 [Full Text]  
• Parrillo, J. E. (2008). Septic Shock -- Vasopressin, Norepinephrine, and Urgency. NEJM 358: 954-956 [Full Text]  
• (2008). Septic Shock: Norepinephrine Alone -- Or with Vasopressin?. JWatch Infect. Diseases 2008: 1-1 [Full Text]